{"transactions":[{"id":857017,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-07T00:48:56.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":900000,"derivative":{"exercise_price":1.84,"expiration_date":"2036-03-05","underlying":"Common Shares","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001193125-26-097181","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526097181/ownership.xml","form_type":"4"}},{"id":906263,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Restricted Stock Units","published_at":"2026-02-14T00:30:03.000Z","date":"2026-02-11","kind":"exercise","planned":false,"acquired":false,"shares":6075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6075},"source":{"system":"sec-edgar","filing":"0001193125-26-052020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052020/ownership.xml","form_type":"4"}},{"id":906262,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2026-02-14T00:30:03.000Z","date":"2026-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2502,"price":1.8,"value":4503.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,075 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":31063,"source":{"system":"sec-edgar","filing":"0001193125-26-052020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052020/ownership.xml","form_type":"4"}},{"id":906261,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2026-02-14T00:30:03.000Z","date":"2026-02-11","kind":"exercise","planned":false,"acquired":true,"shares":6075,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":33565,"source":{"system":"sec-edgar","filing":"0001193125-26-052020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052020/ownership.xml","form_type":"4"}},{"id":962593,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2025-12-20T02:55:03.000Z","date":"2025-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":65,"price":1.68,"value":109.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 1,735 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof."}],"balance_after":27490,"source":{"system":"sec-edgar","filing":"0001193125-25-327279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312525327279/ownership.xml","form_type":"4"}},{"id":962592,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2025-12-20T02:55:03.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":1735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units (\"RSUs\") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units (\"RSUs\") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof."}],"balance_after":27555,"source":{"system":"sec-edgar","filing":"0001193125-25-327279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312525327279/ownership.xml","form_type":"4"}},{"id":1210864,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-03-12T21:30:11.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":750000,"derivative":{"exercise_price":0.53,"expiration_date":"2035-03-10","underlying":"Common Shares","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000950170-25-038113","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025038113/ownership.xml","form_type":"4"}},{"id":1272559,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2025-02-12T21:30:08.000Z","date":"2025-02-11","kind":"exercise","planned":false,"acquired":false,"shares":6076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":6075,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6076},"source":{"system":"sec-edgar","filing":"0000950170-25-018897","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018897/ownership.xml","form_type":"4"}},{"id":1272558,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Shares","published_at":"2025-02-12T21:30:08.000Z","date":"2025-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2440,"price":0.65,"value":1586.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":25820,"source":{"system":"sec-edgar","filing":"0000950170-25-018897","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018897/ownership.xml","form_type":"4"}},{"id":1272557,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Shares","published_at":"2025-02-12T21:30:08.000Z","date":"2025-02-11","kind":"exercise","planned":false,"acquired":true,"shares":6076,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":28260,"source":{"system":"sec-edgar","filing":"0000950170-25-018897","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018897/ownership.xml","form_type":"4"}},{"id":1351683,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Shares","published_at":"2024-11-26T21:55:46.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.6,"value":9000.0,"ownership":{"direct":true},"balance_after":22184,"source":{"system":"sec-edgar","filing":"0000950170-24-131093","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024131093/ownership.xml","form_type":"4"}},{"id":1587955,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-08T21:05:28.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":650000,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-07","underlying":"Common Shares","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001493152-24-009384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224009384/ownership.xml","form_type":"4"}},{"id":1650328,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Restricted Stock Units","published_at":"2024-02-13T02:30:12.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":false,"shares":6076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":12151,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6076},"source":{"system":"sec-edgar","filing":"0001493152-24-005944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005944/ownership.xml","form_type":"4"}},{"id":1650327,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2024-02-13T02:30:12.000Z","date":"2024-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2490,"price":1.08,"value":2689.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":7184,"source":{"system":"sec-edgar","filing":"0001493152-24-005944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005944/ownership.xml","form_type":"4"}},{"id":1650326,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2024-02-13T02:30:12.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":true,"shares":6076,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":9674,"source":{"system":"sec-edgar","filing":"0001493152-24-005944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005944/ownership.xml","form_type":"4"}},{"id":1959833,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-03-11T00:05:09.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":650000,"derivative":{"exercise_price":1.46,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001493152-23-007308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007308/ownership.xml","form_type":"4"}},{"id":2017873,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Restricted Stock Units","published_at":"2023-02-14T21:15:47.000Z","date":"2023-02-11","kind":"exercise","acquired":false,"shares":6076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."}],"balance_after":18227,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6076},"source":{"system":"sec-edgar","filing":"0001493152-23-004899","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004899/ownership.xml","form_type":"4"}},{"id":2017872,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:47.000Z","date":"2023-02-11","kind":"tax_withholding","acquired":false,"shares":2478,"price":1.35,"value":3345.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":3598,"source":{"system":"sec-edgar","filing":"0001493152-23-004899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004899/ownership.xml","form_type":"4"}},{"id":2017871,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:47.000Z","date":"2023-02-11","kind":"exercise","acquired":true,"shares":6076,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":6076,"source":{"system":"sec-edgar","filing":"0001493152-23-004899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004899/ownership.xml","form_type":"4"}},{"id":2338639,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-12T01:44:46.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":650000,"derivative":{"exercise_price":1.4,"expiration_date":"2032-03-10","underlying":"Common Shares","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001493152-22-006698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222006698/ownership.xml","form_type":"4"}},{"id":2395605,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Restricted Stock Units","published_at":"2022-02-16T00:45:49.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":24303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023."}],"balance_after":24303,"derivative":{"underlying":"Common Shares","underlying_shares":24303},"source":{"system":"sec-edgar","filing":"0001493152-22-004720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222004720/ownership.xml","form_type":"4"}},{"id":2582629,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-09-02T20:20:32.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":695000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to one quarter of the shares subject to the option on September 1, 2022, and the balance will vest in 36 successive substantially equal monthly installments thereafter, subject to the reporting person's continuous employment."}],"balance_after":695000,"derivative":{"exercise_price":2.55,"expiration_date":"2031-09-01","underlying":"Common Shares","underlying_shares":695000},"source":{"system":"sec-edgar","filing":"0001493152-21-021880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221021880/ownership.xml","form_type":"4"}}]}